I'm worried.....about my fellow investors ability to acquire shares under .40 cents for much longer...
especially if...
they announce an uptick in enrollment (due to flu resurgence in the US - meaning likely uptick in Sepsis candidates for Tigris in US hospitals, around about now)
or...
the DIMI usability Trial partner is announced and it's a "BIG" player in the dialysis industry...
or...
they finally figure out a way to monetize Dialco, by taking on a new equity partner who will help them get to the multi-billion $ promised land on HHD.
or...
new/hard orders for SAMI that will translate to top line revenue in future Quarters...
Any of these these material events could come at any time. Yikes !
What about a general moarket down-turn after we finish enjoying this bear-market rally? Good thing healthcare is typically a recession proof, and inflation-proof industry (meaning almost limit to what they will spend if it means saving lives). Nov 2021 to Nov 2022 stock performance is evidence of that.
At least key members of their BoD and Baxter, their PMX Distribtuion partner, strongly believe (ie. showing it by putting their money where their mouth is). On the Dialysis side, nice vote of confidence from ARC and the VA in 2022.
MM